This post was originally published on this site

Earlier this fall, we prepared to report Phase III data for tebipenem HBr, our oral medication that, if approved, could help 2.7M patients with serious infections in the US alone go home and stay home from the hospital. By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVCRead More »

The post Playing To Win: Scenario Planning For Binary Readouts In Biotech appeared first on Atlas Venture.